Q BioMed signs Canadian distributor for Strontium89

2020 02 13 23 07 2752 Q Bio Med Strontium89 400

Biotech company Q BioMed has signed an exclusive distribution agreement for its Strontium89 (strontium-89 chloride injection) therapeutic radiopharmaceutical with Canadian distributor isoSolutions Marketing & Management.

Under the deal, isoSolutions will distribute Q BioMed's Strontium89 radiopharmaceutical in Canada for the treatment of painful skeletal metastases. It's available now under Canada's Named Patient Program, according to Q BioMed.

The vendor said it's also actively pursuing full regulatory and marketing approval for Strontium89 in Canada and other markets worldwide.

Page 1 of 436
Next Page